Emuella Flood1, Kavita Gajria2, Vanja Sikirica2, C Noelle Dietrich3, Beverly Romero3, Valerie Harpin4, Tobias Banaschewski5, Javier Quintero6, M Haim Erder2, Moshe Fridman7, Kristina Chen8. 1. ICON Clinical Research, LLC, Gaithersburg, MD, USA. Electronic address: emuella.flood@iconplc.com. 2. Global Health Economics Outcomes Research and Epidemiology, Shire, Wayne, PA, USA. 3. ICON Clinical Research, LLC, Gaithersburg, MD, USA. 4. Ryegate Children's Centre, Sheffield, South Yorkshire, UK. 5. Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim of the University of Heidelberg, Mannheim, Germany. 6. Psychiatry Department, Hospital Universitario Infanta Leonor, Complutense University, Madrid, Spain. 7. AMF Consulting, Inc., Los Angeles, CA, USA. 8. Global Health Economics Outcomes Research and Epidemiology, Shire, Lexington, MA, USA.
Abstract
BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that affects the lives of patients and their families. The Caregiver Perspective on Paediatric ADHD (CAPPA) survey was conducted to evaluate the burden associated with ADHD in Europe and to identify unmet needs. Here, we describe sociodemographic and clinical characteristics, treatment use and impact of ADHD. METHODS: The cross-sectional web-based CAPPA survey was fielded in 10 European countries among caregivers of children/adolescents (aged 6-17 years) with ADHD who were currently receiving or had received pharmacotherapy in the previous 6 months. RESULTS: Data on 3688 completed CAPPA surveys were evaluated. Children/adolescents were diagnosed with ADHD at a mean age of 6.9 years; 80% were male. Most children/adolescents (56%) had undergone behavioural therapy. Overall, 78% of children/adolescents currently received ADHD pharmacotherapy; high rates of atypical antipsychotic use were reported in some countries. Overall, 23% of children/adolescents had repeated a school year and 4% had been expelled recently. Most caregivers (68-88%) reported difficulty with schoolwork, social interactions/activities and family relationships, even when the child/adolescent was receiving ADHD medication. Almost one third (31%) of caregivers felt the need to change employment status despite their child/adolescent receiving ADHD medication in 53% of these cases. LIMITATIONS: Information was reported by caregivers recruited through market research panels; reporting, recall and selection biases may be present. CONCLUSION: Variation across Europe was observed in characteristics of caregivers and children/adolescents with ADHD, and treatment use. Even with medication, ADHD compromised or negatively impacted caregivers' work and children/adolescents' schoolwork, their social interactions and family relationships.
BACKGROUND:Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder that affects the lives of patients and their families. The Caregiver Perspective on Paediatric ADHD (CAPPA) survey was conducted to evaluate the burden associated with ADHD in Europe and to identify unmet needs. Here, we describe sociodemographic and clinical characteristics, treatment use and impact of ADHD. METHODS: The cross-sectional web-based CAPPA survey was fielded in 10 European countries among caregivers of children/adolescents (aged 6-17 years) with ADHD who were currently receiving or had received pharmacotherapy in the previous 6 months. RESULTS: Data on 3688 completed CAPPA surveys were evaluated. Children/adolescents were diagnosed with ADHD at a mean age of 6.9 years; 80% were male. Most children/adolescents (56%) had undergone behavioural therapy. Overall, 78% of children/adolescents currently received ADHD pharmacotherapy; high rates of atypical antipsychotic use were reported in some countries. Overall, 23% of children/adolescents had repeated a school year and 4% had been expelled recently. Most caregivers (68-88%) reported difficulty with schoolwork, social interactions/activities and family relationships, even when the child/adolescent was receiving ADHD medication. Almost one third (31%) of caregivers felt the need to change employment status despite their child/adolescent receiving ADHD medication in 53% of these cases. LIMITATIONS: Information was reported by caregivers recruited through market research panels; reporting, recall and selection biases may be present. CONCLUSION: Variation across Europe was observed in characteristics of caregivers and children/adolescents with ADHD, and treatment use. Even with medication, ADHD compromised or negatively impacted caregivers' work and children/adolescents' schoolwork, their social interactions and family relationships.
Authors: Xin Zhao; Timothy F Page; Amy R Altszuler; William E Pelham; Heidi Kipp; Elizabeth M Gnagy; Stefany Coxe; Nicole K Schatz; Brittany M Merrill; Fiona L Macphee; William E Pelham Journal: J Abnorm Child Psychol Date: 2019-08
Authors: Andrea E Spencer; Rachel Oblath; R Christopher Sheldrick; Lauren C Ng; Michael Silverstein; Arvin Garg Journal: J Atten Disord Date: 2021-03-01 Impact factor: 3.256
Authors: Javier Quintero; Josep A Ramos-Quiroga; Javier San Sebastián; Francisco Montañés; Alberto Fernández-Jaén; José Martínez-Raga; Marta García Giral; Montserrat Graell; María J Mardomingo; César Soutullo; Jesús Eiris; Montserrat Téllez; Montserrat Pamias; Javier Correas; Juncal Sabaté; Laura García-Orti; José A Alda Journal: BMC Psychiatry Date: 2018-02-08 Impact factor: 3.630
Authors: Hannah A Armitt; Ellen N Kingsley; Leah Attwell; Piran C L White; Kat Woolley; Megan Garside; Natasha Green; Michael Hussey; Peter A Coventry Journal: PLoS One Date: 2022-09-20 Impact factor: 3.752